Source: Global Legal Chronicle

Inke: Keensight Capital's Acquisition of Inke

Clifford Chance has advised Neuraxpharm on the deal. Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced [...]

Read full article »

Inke's Competitors | Inke's News | Inke's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

100-250

General Manager

Miquel Bachs Taberner

CEO Approval Rating

90/100

Inke is a Spain-based pharmaceutical company that develops and manufactures active pharmaceutical ingredients for the treatment of respiratory and CNS disorders.